Welcome to our dedicated page for CARLSMED news (Ticker: CARL), a resource for investors and traders seeking the latest updates and insights on CARLSMED stock.
Carlsmed, Inc. (Nasdaq: CARL) is a medical technology company that reports on the commercial progress of its AI-enabled personalized spine surgery platform, aprevo. News about Carlsmed often centers on its revenue growth as a commercial-stage company, updates on surgeon adoption of the aprevo platform, and financial guidance shared in quarterly results and preliminary annual revenue announcements.
Investors following CARL news can expect regular earnings releases that discuss revenue, gross profit, operating expenses, net loss, cash and cash equivalents, and non-GAAP measures such as Adjusted EBITDA. These releases are typically accompanied by conference call and webcast details, and they are referenced in the company’s Form 8-K filings with the SEC. Carlsmed also issues news about amendments to its loan and security agreement and related warrant arrangements, which provide insight into its access to debt financing and capital structure.
Beyond financial updates, Carlsmed publishes news on clinical and product milestones for the aprevo Technology Platform. This includes announcements of clinical study publications in journals such as Global Spine Journal, data presented at meetings like the Scoliosis Research Society Annual Meeting, and the U.S. commercial launch of its aprevo Technology Platform for cervical fusion surgeries. The company’s releases highlight findings on revision rates, mechanical complications, and alignment outcomes when using personalized, patient-specific interbody implants and AI-enabled preoperative planning.
Carlsmed also announces participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and the Piper Sandler Healthcare Conference, as well as index-related developments like its addition to the Russell 2000 Index. These items provide context on how the market and the medical community engage with the company. For ongoing coverage of CARL, this news page aggregates Carlsmed’s financial disclosures, clinical updates, reimbursement developments, and corporate events in one place.
Carlsmed (Nasdaq: CARL) announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion on December 3, 2025, and will present early clinical experience at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting, December 3–6, 2025.
The aprevo® Cervical Interbody System pairs AI-driven preoperative planning with 3D-printed, patient-specific implants. Carlsmed reported its first 50+ cervical cases, noting efficient workflow integration, precise implant fit with maximized endplate coverage, and an ability to achieve planned sagittal and coronal alignment versus stock implants.
Carlsmed referenced prior aprevo® lumbar results showing lower complication rates and fewer revision surgeries, cited 370,000 U.S. cervical fusions performed this year as market context, and will hold a CSRS lunch workshop on Dec 4, 2025 at 12:30 PM EST.
Carlsmed (Nasdaq: CARL) announced that Chairman and CEO Mike Cordonnier will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 from 9:00–9:25 AM ET in New York.
Management will host one-on-one investor meetings, a live webcast will be available to registered participants, and a replay will be posted at https://investors.carlsmed.com/.
Carlsmed (Nasdaq: CARL) reported Q3 2025 revenue of $13.1M, a 98% year‑over‑year increase, gross margin of 75.9%, and cash and equivalents of $115.5M as of September 30, 2025. The company raised full‑year 2025 revenue guidance to $49.0–$50.0M (≈80%–84% growth vs. 2024) and shortened aprevo implant lead times to 8 business days. CMS NTAP reimbursement for aprevo cervical procedures took effect Oct 1, 2025; commercial launch expected early 2026 and >50 cervical procedures completed in clinical evaluation. Carlsmed amended its debt facility to increase availability to $50M and extended maturity and interest‑only period.
Carlsmed (Nasdaq: CARL) will report third quarter 2025 financial results after market close on Thursday, November 6, 2025. Management will host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Participants should dial in 5–10 minutes early and can register via the provided participant registration link. A replay of the webcast will be available shortly after the call and will be archived on the company's investor website.
Carlsmed (Nasdaq: CARL), a medical technology company focused on AI-enabled personalized spine surgery solutions, has appointed Jennifer Kamocsay as Chief Legal Officer and Secretary. Kamocsay brings over 20 years of corporate legal experience from companies including Akoya Biosciences, Rubius Therapeutics, and Progress Software Corporation.
The appointment comes as Carlsmed strengthens its leadership team following its IPO and prepares for its cervical commercial launch. Kamocsay's experience spans corporate governance, securities law, and M&A initiatives, with previous roles at prestigious organizations including Skadden, Arps, Slate, Meagher & Flom LLP.
Carlsmed (Nasdaq: CARL) announced its inclusion in the Russell 2000® Index, effective after market close on September 22, 2025. The addition comes following the company's successful IPO in July 2025 and is part of the planned additions of select IPO companies to the index.
The Russell 2000 Index, which tracks the small-cap segment of the U.S. equity market, is widely used by investment managers and institutional investors, with approximately $9 trillion in assets benchmarked against Russell's U.S. indexes. The index represents about 10% of the total market capitalization of the Russell 3000® Index.
Carlsmed (NASDAQ:CARL), a medical technology company specializing in AI-enabled personalized spine surgery solutions, reported strong Q2 2025 financial results. Revenue reached $12.1 million, marking a 99% year-over-year growth. The company achieved a gross margin of 73.4% and reported a net loss of $6.8 million.
Key highlights include the successful completion of their first personalized cervical spine surgery using the aprevo® technology platform, and receiving CMS New Technology Add-On Payment (NTAP) reimbursement for aprevo® cervical procedures. The company maintains a strong financial position with $33.5 million in cash and recently raised $93.5 million through their IPO in July 2025.
Looking ahead, Carlsmed projects full-year 2025 revenue between $45.5-47.5 million, representing 67-75% growth over 2024.
Carlsmed (NASDAQ:CARL) reported strong Q2 2025 financial results, with revenue reaching $12.1 million, representing a remarkable 99% year-over-year growth. The company achieved a gross profit of $8.9 million with a 73.4% gross margin, though experiencing a slight decrease from 75% in Q2 2024.
Despite the revenue growth, Carlsmed reported a net loss of $6.8 million and an Adjusted EBITDA loss of $6.2 million. The company successfully completed its IPO in July 2025, raising $93.5 million in net proceeds. Looking ahead, Carlsmed projects full-year 2025 revenue between $45.5-$47.5 million, indicating 67-75% growth over 2024.
Notable achievements include the completion of their first personalized cervical spine surgery using the aprevo® technology platform and securing CMS New Technology Add-On Payment (NTAP) reimbursement for aprevo® cervical procedures, effective October 2025.
Carlsmed (Nasdaq: CARL), a medical technology company focused on AI-enabled personalized spine surgery solutions, has scheduled its second quarter 2025 financial results announcement for August 28, 2025, after market close.
The company will host a conference call and webcast at 1:30 PM Pacific Time on the same day. Participants are advised to register 5-10 minutes before the call begins. A replay will be available on the company's website following the event.
Carlsmed (NYSE:CARL) has secured CMS New Technology Add-On Payment (NTAP) approval for cervical fusion procedures using its aprevo® personalized interbody implants. Starting October 1, 2025, hospitals performing qualifying inpatient procedures with aprevo® devices will be eligible for up to $21,125 in additional reimbursement on top of standard Medicare payments.
The NTAP designation recognizes aprevo®'s significant clinical improvements over existing alternatives. The AI-enabled platform creates personalized implants matching each patient's unique anatomy, aiming to reduce revision surgeries. This approval follows the previous year's CMS reimbursement for Carlsmed's lumbar fusion devices. The company expects U.S. commercial launch in 2026, supported by FDA Breakthrough Device designation for cervical use.